Citations

Showing 10 of 107868 citations.

Effect of Ranolazine, an Antianginal Agent With Novel Electrophysiological Properties, on the Incidence of Arrhythmias in Patients With Non–ST-Segment–Elevation Acute Coronary Syndrome
Scirica, Benjamin M. , Hod, Hanoch, Belardinelli, Luiz, Hedgepeth, Chester M., Molhoek, Peter, McCabe, Carolyn H., Morrow, David A. , Murphy, Sabina A. , Verheugt, Freek W.A. , Gersh, Bernard J. , Braunwald, Eugene

Mayo Clinic

Circulation | September 6, 2007 | Volume: 116 | Issue: 15 | Pages: 1647-1652

10.1161/circulationaha.107.724880 | PMID 17804441 Get It

Background— Ranolazine, a piperazine derivative, reduces ischemia via inhibition of the late phase of the inward sodium current (late I Na ) during cardiac repolarization, with a consequent reduction in intracellular sodium and calcium overload. Increased intracellular calcium leads to both mechanical dysfunction and electric instability. Ranolazine reduces proarrhythmic substrate and triggers such as early afterdepolarization in experimental models. However, the potential antiarrhythmic actions of ranolazine have yet to be demonstrated in humans. Methods and Results— The Metabolic Efficiency With Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome (MERLIN)–Thrombolysis in Myocardial Infarction (TIMI) 36 (MERLIN-TIMI 36) trial randomized 6560 patients hospitalized with a non–ST-elevation acute coronary syndrome to ranolazine or placebo in addition to standard therapy. Continuous ECG (Holter) recording was performed for the first 7 days after randomization. A prespecified set of arrhythmias were evaluated by a core laboratory blinded to treatment and outcomes. Of the 6560 patients in MERLIN-TIMI 36, 6351 (97%) had continuous ECG recordings that could be evaluated for arrhythmia analysis. Treatment with ranolazine resulted in significantly lower incidences of arrhythmias. Specifically, fewer patients had an episode of ventricular tachycardia lasting ≥8 beats (166 [5.3%] versus 265 [8.3%]; P <0.001), supraventricular tachycardia (1413 [44.7%] versus 1752 [55.0%]; P <0.001), or new-onset atrial fibrillation (55 [1.7%] versus 75 [2.4%]; P =0.08). In addition, pauses ≥3 seconds were less frequent with ranolazine (97 [3.1%] versus 136 [4.3%]; P =0.01). Conclusions— Ranolazine, an inhibitor of late I Na , appears to have antiarrhythmic effects as assessed by continuous ECG monitoring of patients in the first week after admission for acute coronary syndrome. Studies specifically designed to evaluate the potential role of ranolazine as an antiarrhythmic agent are warranted.
End-of-procedure cefazolin concentrations after administration for prevention of surgical-site infection
Koopman, Erin, Erstad, Brian L. , Demeure, Michael J. , Hayes, Melinda M., Ruth, John T., Matthias, Kathryn R., Koopman, Erin M, Nix, David E.

Mayo Clinic

American Journal of Health-System Pharmacy | September 5, 2007 | Volume: 64 | Issue: 18 | Pages: 1927-1934

10.2146/ajhp070047 | PMID 17823104 Get It

Affinity Thresholds for Membrane Fusion Triggering by Viral Glycoproteins
Hu, Chunling , Nakamura, Takafumi , Marks, James D. , Peng, Kah-Whye , Hasegawa, Kosei , Russell, Stephen J. , Hu, Chunling

Mayo Clinic

Journal of Virology | September 5, 2007 | Volume: 81 | Issue: 23 | Pages: 13149-13157

10.1128/jvi.01415-07 | PMID 17804513 Get It

ABSTRACT Enveloped viruses trigger membrane fusion to gain entry into cells. The receptor affinities of their attachment proteins vary greatly, from 10 −4 M to 10 −9 M, but the significance of this is unknown. Using six retargeted measles viruses that bind to Her-2/neu with a 5-log range in affinity, we show that receptor affinity has little impact on viral attachment but is nevertheless a key determinant of infectivity and intercellular fusion. For a given cell surface receptor density, there is an affinity threshold above which cell-cell fusion proceeds efficiently. Suprathreshold affinities do not further enhance the efficiency of membrane fusion.
Meal Fatty Acid Uptake in Visceral Fat in Women
Votruba, Susanne B. , Mattison, Rebecca S., Dumesic, Daniel A. , Koutsari, Christina , Jensen, Michael D.

Mayo Clinic

Diabetes | September 5, 2007 | Volume: 56 | Issue: 10 | Pages: 2589-2597

10.2337/db07-0439 | PMID 17664244 Get It

OBJECTIVE—Differential meal fat uptake into adipose tissue depots may be a determinant of body fat distribution. RESEARCH DESIGN AND METHODS—We used the meal fat tracer/adipose tissue biopsy approach to compare the effects of meal fat content on the fat uptake into visceral and upper and lower body subcutaneous fat depots in 21 premenopausal women. [3H]triolein was used to trace the fate of fatty acids from a normal-fat or high-fat meal. RESULTS—The proportion of dietary fat uptake into the three depots did not differ between meals; visceral fat accounted for only ∼5% of meal fat disposal irrespective of visceral fat mass. For the women consuming the normal-fat meal, the uptake of meal fatty acid into femoral fat (milligrams meal fat per gram lipid) increased as a function of leg fat mass (r = 0.68, P &lt; 0.05), which we interpret as increased efficiency of uptake. The opposite pattern was seen in omental fat with the normal-fat meal and in all depots after the high-fat meal. For both meals, ∼40% of meal fat was oxidized (3H2O production) after 24 h. CONCLUSIONS—We conclude that greater thigh adipose tissue in women is associated with greater efficiency of meal fat storage under conditions of energy balance, whereas the opposite is seen with visceral fat. These findings imply that different mechanisms may regulate fatty acid uptake in different depots, which may in turn impact on body fat distribution.
Effect of Insulin Deprivation on Muscle Mitochondrial ATP Production and Gene Transcript Levels in Type 1 Diabetic Subjects
Karakelides, Helen, Asmann, Yan W. , Bigelow, Maureen L., Short, Kevin R. , Coenen-Schimke, Jill M., Kahl, Jane, Dhatariya, Ketan , Mukhopadhyay, Debabrata , Nair, K. Sreekumaran

Mayo Clinic

Diabetes | September 5, 2007 | Volume: 56 | Issue: 11 | Pages: 2683-2689

10.2337/db07-0378 | PMID 17660267 Get It

OBJECTIVE—Muscle mitochondrial dysfunction occurs in many insulin-resistant states, such as type 2 diabetes, prompting a hypothesis that mitochondrial dysfunction may cause insulin resistance. We determined the impact of insulin deficiency on muscle mitochondrial ATP production by temporarily depriving type 1 diabetic patients of insulin treatment. RESEARCH DESIGN AND METHODS—We withdrew insulin for 8.6 ± 0.6 h in nine C-peptide–negative type 1 diabetic subjects and measured muscle mitochondrial ATP production and gene transcript levels (gene array and real-time quantitative PCR) and compared with insulin-treated state. We also measured oxygen consumption (indirect calorimetry); plasma levels of glucagon, bicarbonate, and other substrates; and urinary nitrogen. RESULTS—Withdrawal of insulin resulted in increased plasma glucose, branched chain amino acids, nonesterified fatty acids, β-hydroxybutyrate, and urinary nitrogen but no change in bicarbonate. Insulin deprivation decreased muscle mitochondrial ATP production rate (MAPR) despite an increase in whole-body oxygen consumption and altered expression of many muscle mitochondrial gene transcripts. Transcript levels of genes involved in oxidative phosphorylation were decreased, whereas those involved in vascular endothelial growth factor (VEGF) signaling, inflammation, cytoskeleton signaling, and integrin signaling pathways were increased. CONCLUSIONS—Insulin deficiency and associated metabolic changes reduce muscle MAPR and expression of oxidative phosphorylation genes in type 1 diabetes despite an increase in whole-body oxygen consumption. Increase in transcript levels of genes involved in VEGF, inflammation, cytoskeleton, and integrin signaling pathways suggest that vascular factors and cell proliferation that may interact with mitochondrial changes occurred.
Strong Evidence of a Genetic Determinant for Mammographic Density, a Major Risk Factor for Breast Cancer
Vachon, Celine M. , Sellers, Thomas A. , Cunningham, Julie M. , Hilker, Christopher A., Smalley, Regenia L., Schaid, Daniel J. , Kelemen, Linda E. , Vachon, Celine M. , Carlson, Erin E. , Couch, Fergus J. , Pankratz, V. Shane

Mayo Clinic

Cancer Research | September 5, 2007 | Volume: 67 | Issue: 17 | Pages: 8412-8418

10.1158/0008-5472.can-07-1076 | PMID 17804758 Get It

Abstract Increased mammographic density (MD), the proportion of dense tissue visible on a mammogram, is a strong risk factor for breast cancer, common in the population and clusters in families. We conducted the first genome-wide linkage scan to identify genes influencing MD. DNA was obtained from 889 relatives (756 women, 133 men) from 89 families. Percent MD was estimated on 618 (82%) female family members using a validated computer-assisted thresholding method. The genome-wide scan included 403 microsatellite DNA markers with an average spacing of 9 cM. Fine mapping of a region of chromosome 5p (5p13.1-5p15.1) was done using 21 additional closely spaced DNA markers. Linkage analyses were conducted to quantify the evidence for a gene responsible for MD across the genome. The maximum log odds for linkage (LOD) score from the genome-wide scan was on chromosome 5p (LOD = 2.9, supporting linkage by a factor of 102.9 or 794 to 1) with a 1-LOD interval spanning 28.6 cM. Two suggestive regions for linkage were also identified on chromosome 12 (LOD = 2.6, 1-LOD interval of 14.8 cM; and LOD = 2.5, 1-LOD interval of 17.2 cM). Finer mapping of the region surrounding the maximum LOD on chromosome 5p resulted in stronger and statistically significant evidence for linkage (LOD = 4.2) and a narrowed 1-LOD interval (13.4 cM). The putative locus on chromosome 5p is likely to account for up to 22% of variation in MD. Hence, 1 or more of the 45 candidate genes in this region could explain a large proportion of MD and, potentially, breast cancer. [Cancer Res 2007;67(17):8412–8]
Association of Plasma Resistin With Glomerular Filtration Rate and Albuminuria in Hypertensive Adults
Ellington, Allison A., Malik, A. Rauoof , Klee, George G., Turner, Stephen T. , Rule, Andrew D. , Mosley, Thomas H. , Kullo, Iftikhar J.

Mayo Clinic

Hypertension | September 5, 2007 | Volume: 50 | Issue: 4 | Pages: 708-714

10.1161/hypertensionaha.107.095257 | PMID 17785630 Get It

Resistin, a recently discovered proinflammatory cytokine, has been variably associated with insulin resistance, inflammation, and renal dysfunction. We investigated the association of plasma resistin with estimated glomerular filtration rate and albuminuria in 1575 hypertensive adults without known coronary heart disease or stroke (857 blacks and 718 non-Hispanic whites). Resistin was measured by a solid phase sandwich immunoassay, estimated glomerular filtration rate was estimated from serum creatinine, and albuminuria was expressed as urine albumin:creatinine ratio. After adjustment for coronary heart disease risk factors (age, sex, body mass index, smoking history, systolic blood pressure, diabetes, and total and high-density lipoprotein cholesterol) and use of renin-angiotensin blockers and statins, higher plasma resistin levels were associated with lower estimated glomerular filtration rate in both ethnic groups (each P <0.0001); the association remained significant after further adjustment for a marker of insulin resistance (homeostasis model assessment for insulin resistance) and a marker of inflammation (plasma C-reactive protein) and was seen in subjects with and without diabetes (each P <0.0001) in both ethnic groups. Higher plasma resistin levels were associated with a higher urine albumin:creatinine ratio in black subjects with diabetes ( P <0.0001) and non-Hispanic white subjects with diabetes ( P =0.032), independent of coronary heart disease risk factors, hypertension medication use, and statin use; the association remained significant after additional adjustment for homeostasis model assessment for insulin resistance and C-reactive protein. In adults with hypertension, higher circulating resistin levels were associated with a lower estimated glomerular filtration rate and with increased urine albumin:creatinine ratio in the presence of concomitant diabetes. This association was independent of coronary heart disease risk factors and markers of insulin resistance and inflammation.
Iliopsoas impingement after total hip replacement
Dora, Claudio , Houweling, M., Koch, Peter P., Sierra, Rafael J.

Mayo Clinic

The Journal of Bone and Joint Surgery. British volume | September 4, 2007 | Volume: 89-B | Issue: 8 | Pages: 1031-1035

10.1302/0301-620x.89b8.19208 | PMID 17785740 Get It

We have reviewed a group of patients with iliopsoas impingement after total hip replacement with radiological evidence of a well-fixed malpositioned or oversized acetabular component. A consecutive series of 29 patients (30 hips) was assessed. All had undergone a trial of conservative management with no improvement in their symptoms. Eight patients (eight hips) preferred continued conservative management (group 1), and 22 hips had either an iliopsoas tenotomy (group 2) or revision of the acetabular component and debridement of the tendon (group 3), based on clinical and radiological findings. Patients were followed clinically for at least two years, and 19 of the 22 patients (86.4%) who had surgery were contacted by phone at a mean of 7.8 years (5 to 9) post-operatively. Conservative management failed in all eight hips. At the final follow-up, operative treatment resulted in relief of pain in 18 of 22 hips (81.8%), with one hip in group 2 and three in group 3 with continuing symptoms. The Harris Hip Score was significantly better in the combined groups 2 and 3 than in group 1. There was a significant rate of complications in group 3. This group initially had better functional scores, but at final follow-up these were no different from those in group 2. Tenotomy of the iliopsoas and revision of the acetabular component are both successful surgical options. Iliopsoas tenotomy provided the same functional results as revision of the acetabular component and avoided the risks of the latter procedure.
Neurology ® podcasts
Noseworthy, John H., Burns, Ted M.

Mayo Clinic

Neurology | September 4, 2007 | Volume: 69 | Issue: 10 | Pages: 948-948

10.1212/01.wnl.0000281541.78240.9e Get It